Rebiotix is working closely with the U.S. FDA as it conducts an advanced clinical research program

Clinical Trials

Rebiotix conducted three clinical trials of lead Microbiota Restoration Therapy RBX2660 for the prevention of recurrent Clostridium difficile (C. diff) infection, and is currently enrolling in a Phase 3  clinical trial,  in conjunction with the U.S Food and Drug Administration under an Independent New Drug Application.

For currently enrolling clinical trials, go to clinicaltrials.gov.

Important milestones include:

Special FDA designations for RBX2660:

  • Fast Track – May 2013
  • Orphan Drug – March 2014
  • Breakthrough Therapy – October 2015